Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome

İlhan Tarkun, Berrin Çetinarslan, Erdem Türemen, Tayfun Şahin, Zeynep Cantürk and Baki Komsuoğlu

Endocrinology and Metabolism Department, and 1Cardiology Department, Kocaeli University, Turkey

Abstract

Objective: Women with polycystic ovary syndrome (PCOS) exhibit elevated levels of serum C-reactive protein (CRP) and impaired endothelium dysfunction which are directly correlated with insulin resistance. Because rosiglitazone improves insulin sensitivity, we tested whether rosiglitazone treatment ameliorates high-sensitivity (hs)CRP levels and endothelial dysfunction in these patients.

Design: Thirty-one women with PCOS were recruited (mean age, 24.7 ± 3.9 (S.E.) years; mean body mass index (BMI), 25.6 ± 3.2 kg/m²). All women were treated with 4 mg rosiglitazone daily for 12 months.

Methods: Serum levels of testosterone, LH, FSH, sex hormone-binding globulin (SHBG), insulin and hsCRP were measured. The BMI, hirsutism scores and insulin sensitivity indices were calculated before and after treatment. Arterial endothelium and smooth muscle function was measured by examining brachial artery responses to endothelium-dependent and endothelium-independent stimuli before and after treatment.

Results: After treatment with rosiglitazone there were significant decreases in serum testosterone (91.2 ± 37.5 vs 56.1 ± 21.8 ng/dl; P < 0.01) and fasting insulin concentrations (12.5 ± 7.6 vs 8.75 ± 4.03 μU/ml; P = 0.015). Insulin resistance indices were significantly improved after rosiglitazone treatment (P < 0.05). There were no significant changes in BMI, waist circumference, serum total cholesterol, low-density lipoprotein (LDL)-cholesterol, FSH and LH levels. Hirsutism score was decreased significantly after treatment (10.8 ± 1.8 vs 7.6 ± 1.7; P < 0.05). Twenty-four of the women reverted to regular menstrual cycles. Levels of SHBG increased significantly after treatment (28.7 ± 8.7 vs 48.4 ± 11.2 nmol/l; P < 0.01). Serum hsCRP levels were decreased significantly after rosiglitazone treatment (0.25 ± 0.1 vs 0.09 ± 0.02 mg/dl; P = 0.006). There was also significant improvement in endothelium-dependent vascular responses after rosiglitazone treatment (9.9 ± 3.9 vs 16.4 ± 5.1%; P < 0.01).

Conclusions: We conclude that rosiglitazone treatment improves insulin sensitivity in women with PCOS. It also decreases androgen production without significant weight gain. More importantly, it has beneficial effects on endothelial dysfunction and low-grade chronic inflammation in normal weight young women with PCOS.

European Journal of Endocrinology 153 115–121

Introduction

Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism and chronic anovulation but insulin resistance and hyperinsulinism play a critical role in the syndrome pathogenesis (1, 2). Women with PCOS have a clustering of cardiovascular risk factors other than hyperinsulinemia such as obesity, lipid abnormalities, hypertension and changes in fibrinolytic system (3, 4). Over the past 15 years, large epidemiological studies describing cardiovascular disease risk factors among women with PCOS have been carried out (5–8). These studies demonstrated that PCOS women exhibit significantly adverse coronary heart disease (CHD) risk profiles at relatively young age (8), suggesting that these increases may result in premature coronary atherosclerosis. Given the high prevalence of PCOS in the female population, this condition may potentially account for a significant proportion of atherosclerotic heart disease among younger women.

Because CHD is characterized by a long incubation period, metabolic abnormalities observed in the teens
or twenties among PCOS women might translate into measurable vascular abnormalities by middle age. Endothelial dysfunction has been regarded as an early feature of atherosclerosis and plays an important role in the development of atherosclerotic diseases (9, 10). Dysfunction of endothelium cells is probably the earliest event in the process of lesion formation (11). Measures of endothelial dysfunction, such as brachial artery ultrasound, allow for the identification, in a non-invasive manner, of subjects at risk for cardiovascular disease early in its course so that risk-factor modification can be instituted to delay or prevent cardiovascular events. Assessment of endothelial function by measuring flow-mediated dilatation (FMD) of the brachial artery is currently being regarded as a potential tool for predicting CHD (12).

Studies showing a link between endothelial dysfunction and insulin resistance have been reported (13, 14). Endothelial dysfunction might therefore contribute to the increased risk of atherosclerosis in insulin-resistant subjects, such as those with PCOS (15). Accumulating evidence suggests that atherosclerosis represents a chronic inflammatory process and inflammatory markers like C-reactive protein (CRP) provide an adjunctive method for global assessment of cardiovascular risk (16). Previous studies also detected a correlation between insulin resistance and CRP concentrations (17–19). Endothelial dysfunction and high concentrations of high-sensitivity (hs)CRP were detected even in normal-weight women with PCOS (15). Clinical strategies aimed at reducing insulin resistance may prevent early atherosclerosis in women with PCOS. Recently, insulin sensitizers have been used to reduce the level of hyperinsulinemia and its negative impact on ovarian function and possibly to prevent long-term consequences of hyperinsulinemia. Thiazolidinediones (TZDs) are oral anti-diabetic agents that exert their insulin-sensitizing actions through the peroxisome-activated receptor; they are found in a number of tissues including liver, skeletal muscle and adipose tissue. Troglitazone, a member of the TZD family, was found to have beneficial effects on insulin sensitivity and ovarian function in women with PCOS (20–22). In a previous study, endothelial dysfunction in women with PCOS was improved by troglitazone therapy (23). However, troglitazone was taken off the market as a result of concerns over its hepatotoxicity. A newer member of the TZD family, rosiglitazone, was found to have beneficial effects on insulin sensitivity and endothelial dysfunction in both diabetic and non-diabetic patients (24–26). Rosiglitazone may affect inflammatory pathways through transcriptional mechanisms. These anti-inflammatory effects raise the prospect of reduced cardiovascular risk. Currently there are only limited data on the use of rosiglitazone in PCOS.

The aim of our present study is to evaluate the efficiency of rosiglitazone therapy on insulin resistance, serum concentrations of pro-inflammatory markers like hsCRP and endothelial dysfunction in young women with PCOS.

**Materials and methods**

Thirty-one women affected by PCOS (mean age, 24.7±3.9 years) were enrolled in our study. The study protocol was approved by the Ethics Committee for Human Studies of Kocaeli University Hospital. Informed, written consent was obtained from all subjects after explanation of the nature, purpose and potential risks of the study. PCOS was defined when at least two of the following three features were present after the exclusion of other etiologies (Rotterdam criteria) (27): oligo- or anovulation (fewer than six menstrual periods in the preceding year); clinical (Ferriman–Gallwey score >8) (28) and/or biochemical signs of hyperandrogenism and polycystic ovaries. Biochemical criteria included an abnormal luteinizing hormone (LH):follicle-stimulating hormone (FSH) ratio (>2) and/or elevated testosterone levels. The ultrasound criteria used for diagnosis of PCO were: presence of 12 or more follicles in each ovary measuring 2–9 mm in diameter, and/or increased ovarian volume (>10 ml). Oligomenorrhea or amenorrhea were present in 20 of the 31 patients (mean cycle length, 52.7±12.8 days). All women had normal thyroid, renal and hepatic functions. Their prolactin levels were within normal limits. Exclusion criteria for all subjects included: pregnancy or planning pregnancy within a year; current or previous use (within 6 months) of oral contraceptives, anti-androgens, anti-diabetics, statins, glucocorticoids or other hormonal drugs; cigarette smoking; chronic alcohol consumption; blood pressure of ≥130/85 mmHg or treated hypertension; known cardiovascular disease (CVD); hypertension; diabetes mellitus. An overnight dexamethazone suppression test (1 mg) and follicular phase serum 17-OH progesterone determination were performed in order to exclude Cush-ing’s syndrome and late-onset congenital adrenal hyperplasia.

All blood samples were obtained in the morning between 0800 and 0900 h after a 3-day, 300 g carbohydrate diet, an overnight fasting and during early follicular phase. During the same visit all subjects underwent anthropometric measurements, an oral glucose tolerance test and transvaginal ultrasonography. The serum concentrations of FSH, LH, testosterone, prolactin and sex hormone-binding globulin (SHBG) were measured by chemiluminescent enzyme immunoassay (Immulite 2000; Diagnostic Products Corporation, Los Angeles, CA, USA) Serum glucose was measured by using a glucokinase technique. Lipid analysis in fasting serum was performed for all patients. The lipid profile included measurement of the levels of total cholesterol, high- and low-density lipoprotein (HDL and LDL)-cholesterol and triglyceride. These parameters were measured by commercial enzymatic
methods (Aeroset automated analyzer, Abbott Diagnostics, IL, USA). LDL-cholesterol was calculated using Friedewald’s formula.

Plasma insulin levels were measured by chemiluminescent enzyme immunoassay (Immulite 1000 Analyzer) with inter- and intra- assay coefficients of variation (CV) that did not exceed 6.4%. Plasma hsCRP concentrations were measured by chemiluminescent enzyme immunoassay (Immulite 2000) with intra-assay CV of 8.7% and a sensitivity of 0.01 ng/dl. The upper limit of detection was 15 mg/dl.

Insulin resistance was determined by a number of different methods including fasting insulin, the homeostasis model assessment (HOMA) and the quantitative insulin sensitivity check index (QUICKI). The estimate of insulin resistance by HOMA score was calculated using the formula: fasting serum insulin (µU/ml) × fasting plasma glucose (mmol/l)/22.5 (29). The QUICKI is derived by calculating the inverse of the sum of logarithmically expressed values of fasting insulin and glucose (30).

Using ultrasonography, arterial endothelium and smooth muscle function were measured by examining brachial artery responses to endothelium-dependent (FMD) and endothelium-independent stimuli (sublingual nitroglycerin (NTG)). Ultrasonographic measurements were carried out according to the method described by Coretti et al. (31). The assessment was performed after an overnight fast in a quiet, air-conditioned room (22–24°C) by one experienced cardiologist who was blinded to diagnosis. The diameter of the brachial artery was measured on B-mode ultrasound images, using a 7.5 MHz transducer. Ultrasound measurements were obtained using a high-resolution ultrasound machine (Toshiba Power Vision 8000). The right brachial artery was scanned in longitudinal sections 2–8 cm above the elbow. After the detection of the right transducer position, the skin surface was marked and the arm kept in the same position during the study. All scans were recorded on videorecorder and analyzed later. Arterial diameters were measured at rest, during reactive hyperemia (FMD), again at rest and after administration of 0.4 mg sublingual NTG. Reactive hyperemia was induced by inflation of a pneumatic cuff on the upper arm to suprasystolic pressure, followed by cuff deflation after 4.5 min. The diameter of the brachial artery was scanned and recorded after deflation. After 10–15 min rest, the second control scan diameter was recorded. Then sublingual NTG was administered and 3.5–4 min later a final scan of the diameter was recorded.

The end-diastolic arterial diameter was measured from one media-adventitia interface to the other at the clearest section; measurements were taken 3 times at baseline, every 20 s after reactive hyperemia and after administration of NTG. The maximum vessel diameter was defined as the average of the three consecutive maximum diameter measurements after hyperemia and NTG respectively. Vasodilatation by reactive hyperemia or NTG was expressed as the percentage change in diameter compared with baseline values. The intra-observer variation in our clinic was 1.5%.

All of the women were treated with rosiglitazone, 4 mg once a day. Patients were seen every 8 weeks for control of compliance and assessment of side effects. After 12 months of the treatment, the women were admitted to the clinical research center and all of the clinical examinations and laboratory evaluations were repeated. All of the results obtained were then analyzed and pre- and post-treatment values were compared.

**Statistical analysis**

The Statistical Package for the Social Sciences (SPSS version 11.5 for Windows) was used for statistical analysis. The person carrying out the data analysis was blinded to diagnosis. Results are expressed as means±S.D. The characteristics of distribution were tested using the Kolmogorov–Smirnov test. Highly skewed variables were analysed after logarithmic transformation. Spearman’s rank correlations were used for these variables. The Mann–Whitney U-test was used for variables with persisting skewed distribution after log transformation. Differences between means were analyzed using Student’s unpaired t-test using two-tailed tests for significance. P < 0.05 was considered statistically significant. Analysis of correlations between parameters was performed using Pearson’s bivariate correlation coefficient.

**Results**

All of the 31 women who had enrolled completed the study. At the dosage used there were no adverse effects reported by our subjects. During the treatment period no elevations in serum transaminases were detected. Twenty-four of the 31 patients studied reverted to regular ovulatory cycles during the treatment. The length of the cycles at the end of the treatment was 33.7±6.7 days. Clinical characteristics and hormonal parameters of the patients are shown in Table 1. In our study rosiglitazone therapy caused a small (0.8 kg) but non-significant increase in body weight without changes in waist circumferences. There was no significant change in total cholesterol, LDL, LH and FSH levels. The hirsutism score decreased significantly after rosiglitazone treatment (10.8±1.8 vs 7.6±1.7; P < 0.05). Serum triglyceride concentrations were decreased and serum HDL concentrations were increased after treatment but these changes were statistically insignificant (P > 0.05). Serum testosterone levels decreased significantly after rosiglitazone treatment (91.2±37.5 vs 56.1±21.8 ng/dl; P < 0.01) where as SHBG levels increased significantly (28.7±8.7 vs 48.4±11.2 nmol/l; P < 0.01). Serum hsCRP levels
Table 1 Patient characteristics and hormone studies before and after rosiglitazone treatment. Values expressed as means ± S.E.

<table>
<thead>
<tr>
<th></th>
<th>Before rosiglitazone (n = 31)</th>
<th>Post-rosiglitazone (n = 31)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>25.6 ± 3.2</td>
<td>26.3 ± 3.2</td>
<td>0.375</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>81.25 ± 8.04</td>
<td>81.22 ± 8.6</td>
<td>0.448</td>
</tr>
<tr>
<td>Ferriman–Gallwey score</td>
<td>10.8 ± 1.8</td>
<td>7.6 ± 1.7</td>
<td>0.02</td>
</tr>
<tr>
<td>LH (IU/l)</td>
<td>7.9 ± 8.4</td>
<td>8.2 ± 7.3</td>
<td>0.533</td>
</tr>
<tr>
<td>FSH (IU/l)</td>
<td>4.89 ± 2.14</td>
<td>5.9 ± 2.5</td>
<td>0.521</td>
</tr>
<tr>
<td>Testosterone (ng/dl)</td>
<td>91.2 ± 37.5</td>
<td>56.1 ± 21.8</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>SHBG (nmol/l)</td>
<td>28.7 ± 8.7</td>
<td>48.4 ± 11.2</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>163.2 ± 36.8</td>
<td>160.1 ± 38.9</td>
<td>0.456</td>
</tr>
<tr>
<td>Triglyceride (mg/dl)</td>
<td>121 ± 109.48</td>
<td>114.1 ± 75.7</td>
<td>0.095</td>
</tr>
<tr>
<td>HDL-cholesterol (mg/dl)</td>
<td>46.1 ± 11.9</td>
<td>50.4 ± 13.05</td>
<td>0.112</td>
</tr>
<tr>
<td>LDL-cholesterol (mg/dl)</td>
<td>96.41 ± 23.2</td>
<td>100.4 ± 25.5</td>
<td>0.319</td>
</tr>
</tbody>
</table>

Discussion

The endothelium is highly active metabolically and plays a key role in vascular homeostasis through the release of a variety of autocrine and paracrine substances. The healthy endothelium, particularly endothelium-derived nitric oxide (NO), not only modulates the tone of underlying vascular smooth muscle but also inhibits several proatherogenic processes, including monocyte and platelet adhesion, oxidation of LDLs, synthesis of inflammatory cytokines, smooth muscle proliferation and migration, and platelet aggregation; thus exhibiting important anti-atherogenic effects (32). Endothelial dysfunction has been regarded as an early feature of atherosclerosis and plays an important role in the development of atherosclerotic disease (9, 33). Assessment of endothelial function by different methods has emerged as a tool for detection of evidence of preclinical cardiovascular disease (34). Brachial artery ultrasound is a widely used non-invasive measure of endothelial cell function. The forearm blood flow is occluded using a blood pressure cuff maintained at a standard pressure. When pressure is released, reactive hyperemia occurs. This results in shear-stress-induced NO release and subsequent vasodilatation (FMD). This technique has the advantage of being non-invasive and can readily identify populations with attenuated endothelial function. It is particularly well suited for the study of the earliest stages of atherosclerosis in children and young adults, thus providing maximal opportunity for prevention (31). Endothelium-independent stimuli such as nitroprusside or glyceryl trinitrate, which act as NO donors, are used to assess whether the observed findings are secondary to NO-mediated effects or the results of abnormalities of the vascular smooth muscle cells.

Figure 1 hs-CRP concentrations in women with PCOS before and after rosiglitazone treatment.
studies have shown an endothelial dysfunction in women with PCOS (15, 44, 45). Accumulating evidence also suggests that atherosclerosis represents a chronic inflammatory process and inflammatory markers like CRP provide an adjunctive method for global assessment of cardiovascular risk (46, 47). Recent data also suggest that CRP may directly promote endothelial dysfunction by increasing the synthesis of soluble adhesion molecules, increasing monocyte chemotactic protein secretion and facilitating macrophage LDL uptake (48). In previous studies, high hsCRP levels and a link between insulin resistance and elevated CRP levels was shown in women with PCOS (15, 26, 49).

Evidence for a causal role of insulin in the ovarian abnormalities of PCOS is derived from the clinical use of insulin-sensitizing agents. Insulin-sensitizing interventions directly targeting pathogenetic causes of the PCOS may also have beneficial effects on the levels of markers for cardiovascular disease. Since endothelial dysfunction and low-grade chronic inflammation are considered to be an early and necessary abnormality in the pathogenesis of atherosclerosis, we examined the effect of insulin-sensitizing agent rosiglitazone on hsCRP levels and endothelial dysfunction in young women with PCOS. Troglitazone, a peroxisome proliferator-activated receptor δ agonist that has been taken off the market, has been shown to be effective in improving endocrine and ovulatory performance in women with PCOS (21, 22). Previous studies on the effect of rosiglitazone in women with PCOS are limited. Recently, Sepilian et al. (50) reported that rosiglitazone treatment improves ovulatory function and decreases insulin resistance in women with PCOS. We also detected decreased insulin resistance and androgen levels and also improvement of ovulatory cycles in women with PCOS after rosiglitazone treatment. In a recent study, Baillargeon et al. (51) found that insulin-sensitizing drugs increase ovulatory frequency and ameliorate hyperinsulinemia even in non-obese women with PCOS who appear to have normal insulin sensitivity. They suggested that some women with PCOS may have a primary ovarian hyper-responsiveness to insulin without global insulin resistance. Paradisi et al. (23) showed that troglitazone therapy improves endothelial dysfunction in women with PCOS. Pistrosch et al. (24) showed that in type 2 diabetes rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control (24). The effects of rosiglitazone in improving endothelial function were associated with improvement in NO generation (52). Rosiglitazone improves endothelial dysfunction and decrease hsCRP levels in non-diabetic patients with coronary artery disease (25) and also in non-diabetic patients with metabolic syndrome (26). Rosiglitazone exerts a potent anti-inflammatory effect at the cellular and molecular level and in plasma (53). We found that rosiglitazone treatment improves endothelium-dependent vasodilation and decreases serum levels of pro-inflammatory marker hsCRP levels in young women with PCOS. Haffner et al. (54) showed that rosiglitazone reduces serum levels of pro-inflammatory marker CRP in patients with type 2 diabetes.

In conclusion, our results indicate that an insulin-sensitizing drug, rosiglitazone, improves insulin sensitivity in women with PCOS. It also helps to restore ovulation and decrease androgen production without significant weight gain and other side effects. More importantly, these data indicate for the first time that clinical strategies aimed at reducing insulin resistance may have a cardioprotective effect, even in non-obese women with PCOS. Further prospective and placebo controlled studies with larger numbers of patients and long-term follow-up are necessary to determine whether insulin-sensitizing therapy can be useful in modifying cardiovascular risk in women with PCOS.

### Table 2 Glucose metabolism parameters of the patients before and after rosiglitazone therapy. Values expressed as means±S.E.

<table>
<thead>
<tr>
<th></th>
<th>Before rosiglitazone (n = 31)</th>
<th>Post-rosiglitazone (n = 31)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting glucose (mg/dl)</td>
<td>91.4±9.1</td>
<td>87.1±7.65</td>
<td>0.234</td>
</tr>
<tr>
<td>Fasting insulin (µU/ml)</td>
<td>12.5±7.6</td>
<td>8.75±4.03</td>
<td>0.015</td>
</tr>
<tr>
<td>HOMA</td>
<td>2.94±1.8</td>
<td>1.97±0.8</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>QUICKI</td>
<td>0.34±0.02</td>
<td>0.381±0.005</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

### Table 3 Brachial artery responses, expressed as percentage dilatation from baseline.

<table>
<thead>
<tr>
<th></th>
<th>Before rosiglitazone (n = 31)</th>
<th>Post-rosiglitazone (n = 31)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline artery diameter (mm)</td>
<td>3.35±0.27</td>
<td>3.34±0.34</td>
<td>0.815</td>
</tr>
<tr>
<td>FMD (%)</td>
<td>9.9±3.9</td>
<td>16.4±5.1</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>NTG (%)</td>
<td>19.1±5.2</td>
<td>21.1±6.3</td>
<td>0.218</td>
</tr>
</tbody>
</table>
References


4 Tarkun I, Cantürk Z, Arslan BC, Türemen E & Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocrine Journal 2004 51 467–472.


13 Paradisi G, Steinberg HO, Hook G & Baron AD. Troglitazone therapy improves endothelial dysfunction to near normal levels in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 576–580.


26 Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Lovallo J & Dzau VJ. Impaired vasodilation of fore-
arm resistance vessels in hypercholesterolemic humans. *Journal of Clinical Investigations* 1990 **86** 228–234.


Received 1 February 2005
Accepted 13 April 2005